Tedalinab

Tedalinab (GRC-10693) is a drug developed by Glenmark Pharmaceuticals for the treatment of osteoarthritis and neuropathic pain, which acts as a potent and selective cannabinoid CB₂ receptor agonist. It has a very high selectivity of 4700x for CB₂ over the related CB₁ receptor, has good oral bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials.^[1] Many related compounds are known, most of which also show high CB₂ selectivity.^[2]

Tedalinab

Identifiers
IUPAC name (4S,7R)-1-(2,4-difluorophenyl)-N-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-4,7-methano-1H-indazole-3-carboxamide
CAS Number	916591-01-0
PubChem CID	24872953
ChemSpider	29340966
UNII	5R7X34Y6Q1
CompTox Dashboard (EPA)	DTXSID001108817
Chemical and physical data
Formula	C19H21F2N3O
Molar mass	345.394 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)NC(=O)C1=NN(C2=C1[C@@H]3CC[C@H]2C3)C4=C(C=C(C=C4)F)F
InChI InChI=1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1 Key:NTPZXHMTJGOMCJ-WDEREUQCSA-N

See also

• CBS-0550
• Olorinab
• SER-601